购物车
- 全部删除
- 您的购物车当前为空
NSC 228155 是一种 EGFR 的激活剂,与 sEGFR 二聚化结构域 II 结合并调节 EGFR 酪氨酸磷酸化。
为众多的药物研发团队赋能,
让新药发现更简单!
NSC 228155 是一种 EGFR 的激活剂,与 sEGFR 二聚化结构域 II 结合并调节 EGFR 酪氨酸磷酸化。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 279 | 现货 | |
5 mg | ¥ 397 | 现货 | |
10 mg | ¥ 573 | 现货 | |
25 mg | ¥ 1,180 | 现货 | |
50 mg | ¥ 2,320 | 现货 | |
100 mg | ¥ 3,480 | 现货 | |
200 mg | ¥ 4,930 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | NSC 228155 is an activator of EGFR, binding to the sEGFR dimerization domain II and modulate EGFR tyrosine phosphorylation. |
靶点活性 | KIX-KID:0.36 μM |
体外活性 | NSC 228155 promotes transactivation of several RTKs, including ErbB2 and ErbB3, Insulin R and IGF-1 R receptors in the cells. It stimulates dimerization of sEGFR domain II[1]. NSC 228155 can rapidly move across cell membranes and disperse within both cytoplasmic and nuclear compartments. It rapidly generates hydrogen peroxide within cells[2]. NSC 228155 is also a potent inhibitor of KIX-KID interaction(IC50 = 0.36 μM), but it is not particularly selective against CREB-mediated gene transcription in HEK 293T cells[3]. |
细胞实验 | MDA MB468 cells serum-starved overnight are pre-incubated (or not) with 10?μM AG1478 or 2?μM PD 153035 for 90?min and then, where indicated, incubated with 100?μM NSC 228155 or CN 009543V or 150?ng/ml EGF or vehicle (0.2% DMSO) for 15?min. Proteins are blotted to nitrocellulose membrane and analyzed with biotinylated anti-pTyr P100, anti-pEGFR Y1068 and anti-EGFR (epitope in cytoplasmic region) antibodies. (Only for Reference) |
别名 | NSC228155 |
分子量 | 290.25 |
分子式 | C11H6N4O4S |
CAS No. | 113104-25-9 |
Smiles | [O-][N+](=O)c1ccc(Sc2cccc[n+]2[O-])c2nonc12 |
密度 | 1.72 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 12 mg/mL (41.3 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容